Do PPAR-Gamma Agonists Have a Future in Parkinson's Disease Therapy? - Wikidata - awgldk - TriplyDB

Do PPAR-Gamma Agonists Have a Future in Parkinson's Disease Therapy?

Do PPAR-Gamma Agonists Have a Future in Parkinson's Disease Therapy?

http://www.wikidata.org/entity/Q37878285

about

The antidepressant-like effects of pioglitazone in a chronic mild stress mouse model are associated with PPARγ-mediated alteration of microglial activation phenotypes.A synopsis on the role of tyrosine hydroxylase in Parkinson's disease Lack of Genetic Associations of PPAR-γ and PGC-1α with Alzheimer's Disease and Parkinson's Disease with Dementia.PPARγ activation blocks development and reduces established neuropathic pain in rats.Behavioral paradigms to evaluate PPAR modulation in animal models of brain injury.PPARγ and PGC-1α as therapeutic targets in Parkinson's.PPARs in the central nervous system: roles in neurodegeneration and neuroinflammation.Delta-9-tetrahydrocannabinol protects against MPP+ toxicity in SH-SY5Y cells by restoring proteins involved in mitochondrial biogenesis.Cyclooxygenase-2 contributes to oxidopamine-mediated neuronal inflammation and injury via the prostaglandin E2 receptor EP2 subtype.Rosiglitazone synergizes the neuroprotective effects of valproic acid against quinolinic acid-induced neurotoxicity in rats: targeting PPARγ and HDAC pathways.

P2860

Q27303048-EE7D56A7-CC09-45AE-B2A1-1465F2C28245 Q28830946-4DD781CA-BC3B-40AA-ABA1-2B9F63E48837 Q36896649-A8609C38-E984-4C85-92A7-8DE9C82EE772 Q36964445-AD17F8B8-8300-4742-AF89-B1CFF50B255B Q37226637-CB355D46-0ED1-4BBD-93B2-C4F3372DFDDA Q38227702-4229B5E8-FCE5-44EC-B3B4-9CB0DA930DAA Q39145017-0A0FE241-0470-46B3-91C5-6E2997E21928 Q40855302-AB3439B5-B33B-45AA-ACB2-23CEB9BB2616 Q41533962-7293F8AB-9B81-4A22-BC3A-3A364CBFDB29 Q45297835-91B28977-0D18-4D3A-B453-2D66E74DEBDA

P2860

Do PPAR-Gamma Agonists Have a Future in Parkinson's Disease Therapy?

http://www.wikidata.org/entity/Q37878285

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 29 March 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Do PPAR-Gamma Agonists Have a Future in Parkinson's Disease Therapy?

@en

Do PPAR-Gamma Agonists Have a Future in Parkinson's Disease Therapy?

@nl

type

label

Do PPAR-Gamma Agonists Have a Future in Parkinson's Disease Therapy?

@en

Do PPAR-Gamma Agonists Have a Future in Parkinson's Disease Therapy?

@nl

prefLabel

Do PPAR-Gamma Agonists Have a Future in Parkinson's Disease Therapy?

@en

Do PPAR-Gamma Agonists Have a Future in Parkinson's Disease Therapy?

@nl

P1433

Q37878285-599852AA-D568-45DB-B68E-92AEAFCDB36C

P1476

Q37878285-83684BF7-0EE1-4AD8-B893-39FE0BF48EFD

P2093

Q37878285-90E60CBF-C6F1-4A8C-90AA-88D1DAEEE431

Q37878285-F9808142-E3A6-440F-B889-D41969375EB4

P2860

Q37878285-014C9B03-6496-4D51-869E-486220C89455

Q37878285-0784E013-C39D-46B7-AED5-E3A050416B36

Q37878285-092F51B3-9EFA-4F41-B50B-F52F2E5B1A2C

Q37878285-0CEFA54D-22CC-4672-B6BC-EE6142E5E4EB

Q37878285-0E34B0FB-7891-4E72-A174-42D73F0DF818

Q37878285-1063C03D-5A4B-4D86-B5CA-697C8FCAB3AB

Q37878285-111FDEEB-5D7B-4456-993E-B3DDDA58A214

Q37878285-11CE2631-C8EC-48B5-82AE-E3C060072E53

Q37878285-1332E406-BAB0-447C-BBB3-3F03888D2F60

Q37878285-162D34A7-1A6A-4200-A973-EBE6FEC16DE4

P304

Q37878285-5E5A39A7-8286-4939-B5F2-550B359DDE6C

P31

Q37878285-11B19F35-31DC-4CE4-A178-5258585C3C04

P356

Q37878285-25222CBB-372C-4BB5-9D70-A81B39782291

P478

Q37878285-B1046E89-C760-45F8-9A15-D4AE7DD42C6F

P50

Q37878285-8A8C4B69-BD0F-46DB-9145-A4CBE2C83BC9

P577

Q37878285-3EA1C843-CD81-41D1-A4D8-ED33E9126EE0

P5875

Q37878285-14E99F66-3361-4F0E-BCDB-9646CDE694C2

P698

Q37878285-E32F2DD1-EEE0-4BAE-9A51-40F23DC9CA2A

P921

Q37878285-AE964171-E263-44E0-AAE5-9E85CE58E9FB

P932

Q37878285-B6409933-12EF-420A-B404-092A67931422

P356

P1433

Parkinson's disease

P1476

Do PPAR-Gamma Agonists Have a Future in Parkinson's Disease Therapy?

@en

P2093

Anna R Carta

http://www.w3.org/2001/XMLSchema#string

Ezio Carboni

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

Deficiency of TNF receptors suppresses microglial activation and alters the susceptibility of brain regions to MPTP-induced neurotoxicity: role of TNF-alpha1

Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration

Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo

PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro

Peroxisome proliferator-activated receptors, coactivators, and downstream targets

Non-steroidal anti-inflammatory drugs in Parkinson's disease

Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat

Peroxisome proliferator-activated receptors: nuclear control of metabolism

Expression of peroxisome proliferator-activated receptors (PPARs) and retinoic acid receptors (RXRs) in rat cortical neurons

P304

689181

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4061/2011/689181

http://www.w3.org/2001/XMLSchema#string

P478

2011

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-03-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51156766

http://www.w3.org/2001/XMLSchema#string

P698

21603186

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

3096077

http://www.w3.org/2001/XMLSchema#string